Bone Loss Prevention With Zoledronic Acid or Denosumab in Critically Ill Adults
Conditions
Critical Illness · Osteoporosis
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
St Vincent's Health Sydney, Sydney, New South Wales, Australia
Prince of Wales Hospital, Sydney, New South Wales, Australia
Blacktown Hospital, Sydney, New South Wales, Australia
Royal Prince Alfred Hospital, Sydney, New South Wales, Australia
Wollongong Hospital, Illawarra Shoalhaven Health, Wollongong, New South Wales, Australia
Sunshine Coast University Hospital, Birtinya, Queensland, Australia
The Wesley Hospital, Brisbane, Queensland, Australia
Gold Coast University Hospital, Southport, Queensland, Australia
Royal Adelaide Hospital, Adelaide, South Australia, Australia
Barwon Health, University Hospital Geelong, Geelong, Victoria, Australia
Alfred Health, Melbourne, Victoria, Australia
Western Health - Footscray Hospital, Melbourne, Victoria, Australia
Western Health - Sunshine Hospital, Melbourne, Victoria, Australia
Royal Melbourne Hospital, Melbourne, Victoria, Australia
St Vincents Hospital Melbourne, Melbourne, Victoria, Australia
Austin Health, Melbourne, Victoria, Australia
Eastern Health - Box Hill Hospital, Melbourne, Victoria, Australia
St John of God Hospital Subiaco, Perth, Western Australia, Australia
Fiona Stanley Hospital, Perth, Western Australia, Australia
St John of God Hospital Murdoch, Perth, Western Australia, Australia
Auckland City Hospital, Auckland, New Zealand
Wellington Regional Hospital, Wellington, New Zealand
Study leads
Neil Orford, A/Prof
Study Chair
Barwon Health; ANZIC Research Centre
Priya Nair, A/Prof
Study Chair
St Vincent's Health Sydney